Effects of doxazosin and amlodipine on mean platelet volume and serum serotonin level in patients with metabolic syndrome: A randomised, controlled study

Clinical Drug Investigation

Volumn 27, Issue 6, 2007, Pages 435-441

  Demirtunc, Refik ^a   Duman, Dursun ^a   Basar, Melih ^a  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CHOLESTEROL; DOXAZOSIN; GLUCOSE; INSULIN; SEROTONIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; DYSPNEA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID ANALYSIS; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTONIN BLOOD LEVEL; SINGLE BLIND PROCEDURE; SOMNOLENCE; THROMBOCYTE VOLUME;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PLATELETS; DOXAZOSIN; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PLATELET COUNT; PROSPECTIVE STUDIES; SEROTONIN;

EID: 34249944076     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727060-00006     Document Type: Article

References (27)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97
2. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease an update. Hypertension 2001; 37: 1053-9
3. Vinik AI, Erbas T, Park TS, et al. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476-85
4. Bancroft AJ, Abel EW, Mclaren M, et al. Mean platelet volume is a useful parameter: a reproducible routine method using a modified Coulter thrombocytometer. Platelets 2000; 11: 379-87
5. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996; 7: 157-61
6. Thompson CB, Jakubowski JA. Platelet size as a determinant of platelet function. J Lab Clin Med 1983; 101/2: 205-13
7. Jagroop IA, Mikhailidis DP. Doxazosin, an alpha-1-adreceptor antagonist, inhibits serotonin-induced shape change in human platelets. J Hum Hypertens 2001; 15 (3): 203-7 8. Sharpe PC, Trinick T. Mean platelet volume in diabetes mellitus. Q J Med 1993 Nov; 86 (11): 739-42
8. Tschope D, Langer E, Schauseil S, et al. Increased platelet volume: sign of impaired thrombopoiesis in diabetes mellitus. Klin Wochenschr 1989; 15; 67 (4): 253-9
9. Winocour P. Platelets, vascular disease, and diabetes mellitus. Can J Physiol Pharmacol 1994; 72: 295-303
10. Coban E, Ozdogan M, Yazicioglu G, et al. The mean platelet volume in patients with obesity. Int J Clin Pract 2005 Aug; 59 (8): 981-2
11. Pietraszek MH, Takada Y, Takada A, et al. Blood serotonergic mechanisms in type 2 (non-insulin-dependent) diabetes mellitus. Thromb Res 1992; 66 (6): 765-74
12. Barradas MA, Gill DS, Fonseca VA, et al. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest 1988; 18 (4): 399-404
13. Malyszko J, Malyszko J, Myśliwiec M. Blood platelet function, plasma serotonin and lipid metabolism in patients with diabetic nephropathy [in Polish]. Pol Arch Med Wewn 1995; 94 (1): 26-31
14. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study: a novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1992 Aug; 1 (2): 113-9
15. Haffner SM, Kennedy E, Gonzalez C, et al. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 1996 Oct; 19 (10): 1138-41
16. Reusch JEB. Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. Am J Cardiol 2002; 90: 19G-26G
17. McCarty MF. Hemostatic concomitants of syndrome X. Med Hypotheses 1995; 44 (3): 179-93
18. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev 2002; 3 (2): 85-101
19. Dell'Omo G, Penno G, Pucci L, et al. The vascular effects of doxazosin in hypertension complicated by metabolic syndrome. Coron Artery Dis 2005; 16 (1): 67-73
20. Cox D. Methods for monitoring platelet function. Am Heart J 1998; 135: 160-9
21. Van der Loo B, Martin JF. A role for changes in platelet production in the cause of acute coronary syndromes. Arterioscler Thromb Vasc Biol 1999; 19: 672-9
22. Hendra TJ, Oswald GA, Yudkin JS. Increased mean platelet volume after acute myocardial infarction relates to diabetes and to cardiac failure. Diabetes Res Clin Practice 1988; 5: 63-9
23. Smyth DW, Martin JF, Michalis L, et al. Influence of platelet size before coronary angioplasty on subsequent restenosis. Eur J Clin Invest 1993; 23: 361-7
24. O'Malley T, Langhorne P, Elton RA, et al. Platelet size in stroke patients. Stroke 1995; 26: 995-9
25. Bath PMW, Missouris CG, Buckenham T, et al. Increased platelet volume and platelet mass in patients with atherosclerotic renal artery stenosis. Clin Sci 1994; 87: 253-7
26. Tschoepe D, Roesen P, Esser J, et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 1991; 17: 433-9
27. Winocour P. Platelet abnormalities in diabetes mellitus. Diabetes 1992; 41: 26-31